Estetrol for COVID-19: real-time analysis

Download Image

Post

c19early.org

Estetrol for COVID-19

1 study with 171 patients

Serious outcome risk

Estetrol

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Estetrol studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−102%

Mortality (1)−102%

RCTs (1)−102%

Late (1)−102%

00.511.5+

← Estetrol
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Jun 8 2023	Foidart et al., Journal of Clinical Medicine, doi:10.3390/jcm12123928	Estetrol Is Safe and Well Tolerated during Treatment of Hospitalized Men and Women with Moderate COVID-19 in a Randomized, Double-Blind Study
Jun 8 2023	102% higher mortality (p=0.33) and 117% worse recovery (p=0.07). RCT 175 hospitalized patients with moderate COVID-19 showing no significant benefit with estetrol (E4) treatment.